Physician profile
Kim M Goodwin
NPI 1669426276
$1,800.52
in general payments reported to CMS, 2019-2025
28 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $115 · 2021: $218 · 2022: $267 · 2023: $297 · 2024: $186 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.04 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $179.23 | 2022-2025 | |
| Myovant Sciences INC. | $163.86 | 2021-2022 | |
| Hologic Sales and Service, LLC | $117.48 | 2020-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Daiichi Sankyo INC. | $104.40 | 2019-2022 | |
| Myriad Women'S Health, INC. | $68.49 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $59.21 | 2019-2025 | |
| Astellas Pharma US INC | $50.69 | 2024-2025 | Veozah |
| Allergan, INC. | $48.57 | 2019 | |
| Pfizer INC. | $47.82 | 2021-2023 | |
| Minerva Surgical, INC | $43.31 | 2019-2021 | |
| Lupin INC. | $40.38 | 2019 | |
| Millicent US INC | $39.71 | 2024-2025 | Intrarosa, Femring |
| Baxter Healthcare | $30.82 | 2025 | Seprafilm |
| Sumitomo Pharma America, INC. | $29.75 | 2023 | Myfembree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $29.20 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $28.70 | 2020 | |
| Organon LLC | $27.10 | 2022 | |
| Therapeuticsmd, INC. | $26.13 | 2019-2021 | |
| Biogen, INC. | $21.83 | 2024 | |
| Duchesnay USA Incorporated | $19.74 | 2019 | |
| Becton, Dickinson and Company | $19.30 | 2023 | Bd Onclarity |
| Coopersurgical, INC. | $19.03 | 2019 | |
| Meditrina | $17.93 | 2025 | |
| Ethicon US, LLC | $17.52 | 2019 | |
| Exeltis, USA INC. | $15.08 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.75 | 2019 | |
| Channel Medsystems, INC. | $8.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.